Committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders


Sage Therapeutics (NASDAQ: SAGE) is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage has a portfolio of novel product candidates targeting critical CNS receptor systems, GABA and NMDA. Sage's lead program, a proprietary IV formulation of brexanolone (SAGE-547), has completed two Phase 3 clinical trials in postpartum depression.


Year Invested: 2011
Location: Cambridge, Mass.
Visit: www.sagerx.com

Recent News

February 19, 2019
Sage Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline and Business Progress

February 7, 2019
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

February 5, 2019
Sage Therapeutics to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 19, 2019

Read More News

Associated Team Members

Kevin Starr
Partner